Document is current

Article History

Received: 20 February 2025

Accepted: 22 May 2025

First Online: 6 June 2025

Declarations

:

: Not applicable.

: Not applicable.

: Niels Teich reports personal fees from AbbVie, Falk, Fering, Pfizer, Galapagos and Takeda outside the submitted work. Axel Dignass reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees from Abivax, AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb/Celgene, Dr Falk Foundation, Galapagos, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, Dr Falk Foundation, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Biogen, CED Service GmbH, Celltrion, Falk Foundation, Ferring, Galapagos, Gilead, High5MD, Janssen, Materia Prima, MedToday, MSD, Pfizer, Streamed-Up, Takeda, Tillotts, and Vifor Pharma; payment for manuscript prep-aration from Falk Foundation, Takeda, Thieme, and UniMed Verlag. Ines Weinhold and Julia Borchert declare that there are no conflicts of interest with regard to the research, authorship and/or publication of this abstract. Both are employees of WIG2 GmbH. WIG2 GmbH received funding from Takeda Pharma Vertrieb GmbH & Co. KG for the conduct of the study. Juliane Sünwoldt, Christina Dünweber, Robert Kudernatsch and Stephan Kaiser are employees of Takeda Pharma Vertrieb GmbH & Co.KG. They hold no Takeda stock or stock options. This study was funded by Takeda Pharma Vertrieb GmbH & Co.KG.